Wu Jiang, Ku Stephen C, Ko Andrew L
Department of Anesthesiology and Pain Medicine, University of Washington , Seattle , Washington , USA .
Department of Neurological Surgery, University of Washington , Seattle , Washington , USA .
J Pain Palliat Care Pharmacother. 2019 Mar-Jun;33(1-2):49-53. doi: 10.1080/15360288.2019.1651439. Epub 2019 Aug 29.
A 51-year-old man with metastatic renal cell carcinoma whose fentanyl requirement was 3000-4000 µg/h in inpatient hospice presented for a thoracic (T) vertebral 4-10 posterior spinal fusion for a lytic T7 compression fracture. He underwent total intravenous (IV) anesthesia with propofol, remifentanil, and ketamine; liposome bupivacaine was locally infiltrated at the end of the case. Following extubation on postoperative day (POD) 1, he had severe pain refractory to high-dose IV fentanyl patient control analgesia and ketamine infusion. His pain dramatically improved after a dexmedetomidine infusion was added and titrated to the analgesic effect. He participated in neurological examinations and fulfilled both surgical and pain management goals without side effects. Dexmedetomidine was successfully weaned off on POD 3.
一名51岁的转移性肾细胞癌男性患者,其在住院临终关怀时芬太尼需求量为3000 - 4000微克/小时,因T7溶骨性压缩骨折行胸段(T)4 - 10椎体后路脊柱融合术。他接受了丙泊酚、瑞芬太尼和氯胺酮的全静脉麻醉;手术结束时局部浸润了脂质体布比卡因。术后第1天拔管后,他出现严重疼痛,高剂量静脉注射芬太尼患者自控镇痛和氯胺酮输注均难以缓解。添加右美托咪定输注并滴定至镇痛效果后,他的疼痛显著改善。他参与了神经学检查,实现了手术和疼痛管理目标,且无副作用。右美托咪定在术后第3天成功停用。